SCHEMBL6790528

SCHEMBL6790528

C/C(=C/C(=O)Nc1ncccc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.69
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HSP90AA1 P07900 1/20 0.47
DHODH Q02127 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
LMNA P02545 3/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.42
HTT P42858 3/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29355750 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL30760782 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL29362821 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL16964998 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL4022937 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL29966843 0.82 TERT (1.00) TERTNPC1RAB9AALDH1A1DHODH
SCHEMBL6786614 0.81 TERT (0.59) TERTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4025006 0.80 TERT (0.73) TERTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6783614 0.80 TERT (0.81) TERTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4024968 0.79 TERT (0.75) TERTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885NPC1 3387/4885RAB9A 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.